CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024
- Written by PR Newswire
![]() |
SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the initial results from the ongoing first-in-human study of CT071 have been presented at the 29th Annual Congress...
Read more: CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024















